Fiche publication
Date publication
août 2022
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Caron B, D'Amico F, Jairath V, Netter P, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Medical treatment for inflammatory bowel disease has advanced significantly over the two past decades. The advent of biologics and small molecules has revolutionized outcomes of patients with inflammatory bowel disease. Knowledge of drug pharmacology, indications, and adverse events is essential to ensure the best clinical care while minimizing toxicity. Our aim was to review the literature on current methods of benefit-risk assessment, and consider their practical applicability to inflammatory bowel disease.
Mots clés
benefit, inflammatory bowel disease, risk
Référence
J Crohns Colitis. 2022 08 11;:
